Keywords: Takeda, Fate Therapeutics, Regenerative medicines, Stem cell pathways

Takeda takes stake in USA-based Fate Therapeutics to expand in regenerative medicines

Article | 11 May 2011

Print This

Japan’s largest drugmaker Takeda Pharmaceutical (TSE: 4502) has made an equity investment in privately-held Fate Therapeutics, via its Takeda ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in